AzTrials
AzTrials

LobectomyTHYRORALNCT07055191

TOETVA Technique Compared With Anterior Cervical Thyroidectomy (AC) in Terms of Efficacy and Safety

A study testing Transoral Endoscopic Thyroidectomy by Vestibular Approach and Anterior Cervical thyroidectomy in people with Lobectomy and Thyroidectomy, run by University Hospital, Lille at 10 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Nearly 50,000 thyroidectomies are performed in France each year for benign and malignant pathologies. Each one affects the life of the patient and represents, for some, suffering, symbolized by the stigma of the operation. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Lobectomy, Thyroidectomy
What is being tested?
Transoral Endoscopic Thyroidectomy by Vestibular Approach and Anterior Cervical thyroidectomy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
616 participants
Where
10 sitesFrance
Study dates
7 Nov 2025to Nov 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with a surgical indication for lobectomy or thyroidectomy
  • Estimated thyroid volume measured by ultrasonography of less than 60 mL
  • Nodules suspected to be malignant measuring less than 4 cm
  • Patient aged between 18 and 65 years old
  • Patient who has benefited from an endocrinological evaluation, with a favorable opinion for TOETVA or AC Patient who understands and accepts the need for follow-up
  • Patient who agrees to be included in the study and who signs the informed consent form
  • Patient affiliated to a healthcare insurance plan

Who cannot join

  • Patients refusing an alternative to AC or refusing AC
  • History of cervical surgery
  • Associated parathyroid surgery
  • Identification of malignant lymph nodes
  • Presence of a severe and evolutive life threatening pathology
  • Patients with unstable psychiatric disorder, under supervision or guardianship
Show all 11Show fewer
  • Patient who does not understand French/ is unable to give consent
  • Patient not affiliated to a French or European healthcare insurance
  • Patient who has already been included in a trial which has a conflict of interests with the present study
  • Pregnant or breast-feeding patient
  • Patient incarcerated

Trial locations and contacts

10 sites in 1 country. Contact the study team or a site near you to ask about taking part.

10 sites in 1 country

France10 sites, 10 recruiting
  • AP-HP - Hôpital Avicennes

    Bobigny

    Christophe Tresallet, Doc., +33(0)1 48 02 61 95, christophe.tresallet@aphp.fr

    Not yet recruiting
  • Hôpital Franco-Britannique

    Levallois-Perret

    Grégoire Deroide, Doc., +33(0)1 56 83 08 84, gregoire.deroide@gmail.com

    Not yet recruiting
  • CHU de Lille, Hôpital Huriez

    Lille

    Robert Caiazzo, Prof., +33(0)320445515, robert.caiazzo@chu-lille.fr

    Recruiting
  • CHU Dupuytren

    Limoges

    Muriel Mathonnet, Prof., +33(0)5 55 05 62 12, mathonnet@unilim.fr

    Not yet recruiting
  • CHU de Nantes - Hôtel Dieu

    Nantes

    Eric Mirallié, Prof., +33(0)2 40 08 31 66, eric.mirallie@chu-nantes.fr

    Not yet recruiting
  • AP-HP - Hôpital Cochin

    Paris

    Martin Gaillard, Doc., +33(0)1 58 41 17 58, martin.gaillard@aphp.fr

    Not yet recruiting
  • Hôpital Lyon Sud

    Pierre-Bénite

    Laure Maillard, Doc., +33(0)4 78 86 23 70, laure.maillard@chu-lyon.fr

    Not yet recruiting
  • CHU de Poitiers

    Poitiers

    Gianluca Donatini, Doc., +33(0)5 49 44 43 21, Gianluca.donatini@chu-poitiers.fr

    Not yet recruiting
  • Polyclinique de la Côte Basque Sud

    Saint-Jean-de-Luz

    Isabelle Honigman-Bueno, Doc., +33(0)5 59 51 63 67, drhonigmanbueno@gmail.com

    Not yet recruiting
  • CHRU de Nancy Brabois

    Vandœuvre-lès-Nancy

    Nominé-Criqui Claire, Doc., +33(0)3 83 15 78 26, c.nomine-criqui@chru-nancy.fr

    Not yet recruiting

Other trials in France

About this study

Official title: Prospective Randomized Multicenter Trial Comparing the Efficacy and Safety of the Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA) Versus Anterior Cervical Thyroidectomy (AC)

Nearly 50,000 thyroidectomies are performed in France each year for benign and malignant pathologies. Each one affects the life of the patient and represents, for some, suffering, symbolized by the stigma of the operation. The consequences of these scars vary according to the patient, their experience and their culture. For example, cervicotomies are particularly badly accepted in Asia since they are supposed to interrupt the fertility meridian. In France, increasing attention is being paid to the global management of a person with some disease. As a disease state may be transitory, the medical team must consider the situation "after the illness" and plan a return to normality. In particular, alternative approaches to cervicotomy have been developed, in which the scar is in a less visible location, at the cost of a more extensive dissection. These techniques include the transaxillary approach, the bi-areolar biaxillary approach and the retroauricular approach. Such procedures, initially developed as an endoscopic approach, have become progressively robotically assisted, to help with the ergonomics of the procedure. Even though robotic assistance initially helped to spread use of these techniques, it has, over time, limited them, first because of higher cost, and second because of the high learning curve (50 to 75 cases). Finally, the transaxillary approach, which is the most commonly performed, has an inherent problem due to the decreased visibility of the noble structures on the contralateral side, leading to frequent subtotal resection.

Since 2014, the Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA) has been developed as an alternative to these robot-assisted procedures. Because this technique offers the surgeon similar access to the anatomical structures on both sides of the trachea and makes it possible to identify the noble structures to be preserved, TOETVA is currently undergoing a more widespread use in France and worldwide and more candidates for are being offered the procedure. TOETVA reduces the need for dissection to reach the thyroid gland. Moreover, this procedure does not require any special equipment, even if robotic assistance has been used in transoral thyroidectomy.

Read more

Just like the electric light was not developed from the continuous improvement of candles, entirely new approaches are sometimes necessary in surgery. The Scientific Committee of the French Association of Endocrine Surgery is convinced that TOETVA, will become more widely used in France, even if this technique is a major departure from the standard approach. However, it is technically more demanding and must, therefore, be evaluated and supervised. This will require a safety study and a comparison with the current reference procedure, the anterior cervical thyroidectomy (AC). The investigators assume, based on our initial experience, that the use of endoscopic equipment and its magnification will allow good visualization of the noble elements (recurrent nerve and parathyroid glands) and that the complication rate of TOETVA will not be higher than that of the reference approach.

The investigators propose to evaluate, through a prospective randomized study, an innovative endocrine surgical technique that has started to be used worldwide. Although this study is in line with the objectives of an evaluation of the pertinence of care by the health authorities, it would be the first assessment of this innovative surgical technique in thyroid surgery. To our knowledge, after an extensive bibliographic search, no prospective multicenter randomized trial comparing TOETVA to AC has yet been performed, even if many cohorts of patients have been reported to have benefited from this approach6.

In this trial, any change to the quality of life will be extensively evaluated. The use of validated scores to quantify pain and quality of life will provide objective information and make it possible to determine the impact of the presence or absence of a scar.

Being tested
Transoral Endoscopic Thyroidectomy by Vestibular Approach, Anterior Cervical thyroidectomy
Keywords
Endocrinology, thyroidectomy, mini-invasive, TransOral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA), Anterior Cervical thyroidectomy (AC)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transoral Endoscopic Thyroidectomy by Vestibular ApproachProcedure or surgery

    Transoral Endoscopic Thyroidectomy by Vestibular Approach

  • Anterior Cervical thyroidectomyProcedure or surgery

    Anterior Cervical thyroidectomy

Study groups in NCT07055191
Study groupRoleWhat they receive
Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA)ExperimentalNot described
Receives: Procedure: Transoral Endoscopic Thyroidectomy by Vestibular Approach
Anterior Cervical thyroidectomy (AC)Active comparatorNot described
Receives: Procedure: Anterior Cervical thyroidectomy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To demonstrate the non-inferiority of TOETVA compared to AC in terms of early postoperative complications (during the first 24 hours) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure.

    The rate of patients with early postoperative complications defined by the occurrence of at least one of the following events within the first 24 hours:

    • Recurrent paralysis, defined by abnormal vocal cord mobility;
    • Hypoparathyroidism: defined by calcium level<80 mg/L and/or parathyroid hormone level<15 pg/mL;
    • Hematoma: defined by the need for additional surgery to drain the hematoma

    Measured: during the first 24 hours

Secondary outcomes (5)
  1. To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the rate of mid-term postoperative complications

    The rate of patients with mid-term postoperative complications defined by the occurrence of at least one of the following events within the 30 postoperative days:

    • Symptomatic hypocalcemia secondary to hypoparathyroidism: defined by initiation of calcium supplementation;
    • Hematoma: defined by the a revision surgery for hematoma;
    • Infection: defined by revision surgery for infection or the initiation of an antibiotic therapy, apart from perioperative antibiotic prophylaxis for the TOETVA group.

    Measured: within 30 days of surgery

  2. To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the quality of life at 1 month after surgery

    Quality of life scores assessed at 1 month using the 36-Item Short Form Survey (SF-36), the Voice handicap index (VHI) and the Swallowing Impairment Score (SIS) questionnaires.

    SF36: score from 0 to 100. Higher scores mean a better outcome. VHI: score from 0 to 120. Higher scores mean a worse outcome. SIS: score from 0 to 24. Higher scores mean a worse outcome.

    Measured: at 1 month after surgery

  3. To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the quality of life at 6 months after surgery

    Quality of life scores assessed at 6 months using the 36-Item Short Form Survey (SF-36), the Voice handicap index (VHI) and the Swallowing Impairment Score (SIS) questionnaires.

    SF36: score from 0 to 100. Higher scores mean a better outcome. VHI: score from 0 to 120. Higher scores mean a worse outcome. SIS: score from 0 to 24. Higher scores mean a worse outcome.

    Measured: at 6 months after surgery

  4. To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the evolution of pain at 1 month after surgery

    Change in pain at 1 month from baseline (preoperative assessment), assessed using two validated scores: (1) the visual analogue scale (VAS) in five areas (lower lip, chin, jaw, anterior neck, and cervix/back) and during four actions (swallowing, brushing teeth, speaking, and shaving), which is the only one that has been validated for TOETVA and (2) the DN4 (Neuropathic Pain 4 Questions), which is widely used in the literature.

    Measured: at 1 month after surgery

  5. To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the evolution of pain at 6 months after surgery

    Change in pain at 6 months from baseline (preoperative assessment), assessed using two validated scores: (1) the visual analogue scale (VAS) in five areas (lower lip, chin, jaw, anterior neck, and cervix/back) and during four actions (swallowing, brushing teeth, speaking, and shaving), which is the only one that has been validated for TOETVA and (2) the DN4 (Neuropathic Pain 4 Questions), which is widely used in the literature.

    Measured: at 6 months after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jul 2025
  2. Study start7 Nov 2025
  3. Primary completionNov 2028 (estimated)
  4. Study completionNov 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
616 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07055191
Sponsor's protocol ID
2022_0509
Other IDs
PHRC-21-0340, 2022-A02301-42
Acronym
THYRORAL
Status last verified
Jan 2026
First submitted
3 Mar 2025
Last updated
16 Jan 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Transoral Endoscopic Thyroidectomy by Vestibular Approach and Anterior Cervical thyroidectomy in people with Lobectomy and Thyroidectomy, run by University Hospital, Lille at 10 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 16 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 10 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Robert Caiazzo, Prof. (+33 (0)3 20 44 55 15, robert.caiazzo@chu-lille.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To demonstrate the non-inferiority of TOETVA compared to AC in terms of early postoperative complications (during the first 24 hours) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure. (time frame: during the first 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in